Edgewise Therapeutics’ Phase 2 HCM data put systolic function into sharper focus
Find out how Edgewise Therapeutics’ EDG-7500 data could reshape HCM drug development as Phase 3 questions emerge.
Pharma & Biotech
Pharma & Biotech
Oral Pompe therapy S-606001 moves to Phase 2 as Shionogi expands rare disease focus
Shionogi's S-606001 enters global Phase 2 as the first oral GYS1 inhibitor tested as an add-on to ERT in late-onset Pompe disease. Read the analysis.
Pharma & Biotech
Coya Therapeutics expands ALS trial into Canada as COYA 302 gains Health Canada clearance
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.